Delta 9 THC has not been definitively proven to cause cancer in humans, but the picture is more complicated than a simple yes or no. Some evidence links heavy, long-term cannabis smoking to increased lung and testicular cancer risk, while lab studies show THC can actually kill certain cancer cells. The method of consumption matters enormously: smoking introduces combustion byproducts that are known carcinogens, while the THC molecule itself has a more ambiguous relationship with cancer.
What Smoking Does to Cancer Risk
When you burn cannabis and inhale the smoke, you’re exposed to many of the same carcinogens found in tobacco smoke, including polycyclic aromatic hydrocarbons (PAHs) and benzene. A study in Nicotine & Tobacco Research found that people who smoked both cannabis and cigarettes had significantly higher levels of PAH and benzene biomarkers than people who smoked only cigarettes. That’s notable because those specific compounds are established cancer-causing agents.
A case-control study published in the European Respiratory Journal found that lung cancer risk increased 8% for each “joint-year” of cannabis smoking, after adjusting for cigarette use and other factors. For comparison, each pack-year of cigarette smoking raised risk by 7%. People in the highest third of cannabis use had a lung cancer risk 5.7 times higher than non-users. However, when researchers simply compared cannabis smokers to non-smokers overall, the association was weaker and not statistically significant, with a relative risk of 1.2. The wide confidence intervals in these findings reflect a common problem in cannabis research: relatively small study sizes and difficulty separating cannabis effects from tobacco effects, since many cannabis smokers also smoke cigarettes.
The key distinction here is between the delivery method and the compound itself. Combustion creates carcinogens regardless of what’s being burned. Edibles and other non-smoked forms of delta 9 THC bypass this problem entirely, eliminating exposure to the combustion byproducts that drive smoking-related cancer risk.
The Testicular Cancer Connection
Testicular cancer is the one cancer type where a link to cannabis use, not just smoking, appears more consistent across studies. A 2024 meta-analysis in BJU International pooled data from five studies and found that current cannabis users had a 62% higher risk of testicular germ cell tumors compared to non-users. Long-term use of 10 years or more raised the risk by 68%. The association was strongest for a specific subtype called non-seminomatous germ cell tumors, where cannabis users faced 71% higher odds.
These are meaningful increases, though testicular cancer is relatively rare to begin with, affecting roughly 1 in 250 men over a lifetime. A 62% increase on a small baseline risk still results in a small absolute risk. Researchers haven’t pinpointed why this association exists, and it’s possible that other lifestyle factors common among cannabis users play a role. Still, the consistency across multiple studies makes this the strongest cancer signal tied to cannabis use itself rather than just to smoking.
THC Can Damage DNA
At the cellular level, there’s evidence that cannabinoids, including delta 9 THC, can cause genetic damage. Research published in Addiction Biology identified that the core chemical structure shared by all cannabinoids, a component called the olivetol nucleus, can directly damage genetic material. This finding applies broadly across cannabinoid types, not just THC, and has been demonstrated in both normal cells and multiple cancer cell lines, including head and neck, cervical, gastric, ovarian, and colorectal cancers.
DNA damage doesn’t automatically lead to cancer. Your body has repair mechanisms that fix most genetic errors. But accumulated, unrepaired damage over time is one of the fundamental ways cancer develops, so this finding is relevant to the question of long-term risk.
THC Also Kills Cancer Cells in the Lab
Here’s where the story gets paradoxical. While THC may damage DNA, extensive lab research shows it can also trigger cancer cell death through multiple pathways. In colorectal cancer cells, THC shuts down key survival signals that keep cancer cells alive, pushing them into programmed cell death. In glioblastoma, the most aggressive type of brain cancer, THC blocks cancer cells from progressing through their growth cycle.
Lab studies on estrogen-sensitive breast cancer cells found that THC suppressed the growth of these cells by interfering with estrogen signaling. Specifically, THC boosted levels of a protein that acts as a brake on the estrogen-driven growth pathway. The effect was stronger when estrogen was present, meaning THC appeared to counteract one of the hormonal signals that fuels these tumors.
These anti-cancer effects have even shown up in small human trials. In a pilot study, THC was administered directly into brain tumors of nine patients with recurring glioblastoma, and it decreased tumor cell proliferation in two of them. A later trial combining THC and CBD with standard chemotherapy in 21 glioblastoma patients produced striking results: the combination group had an 83% one-year survival rate compared to 44% in the chemotherapy-only group, with median survival nearly doubling from 369 days to over 662 days.
These are small trials, and the results need confirmation in larger studies. But they illustrate that the relationship between THC and cancer is not a straightforward “causes it” or “prevents it” scenario. The effect appears to depend on the cancer type, the dose, and the biological context.
FDA-Approved THC Products for Cancer Patients
The FDA has approved synthetic versions of delta 9 THC, sold as Marinol and Syndros, specifically for cancer patients. These medications treat nausea from chemotherapy and are also approved for appetite loss in AIDS patients. A third drug, Cesamet, contains a compound chemically similar to THC and carries the same nausea indication. None of these are approved as cancer treatments. They manage side effects of cancer therapy, not the disease itself.
How Consumption Method Changes Your Risk
If your concern is cancer, how you consume delta 9 matters far more than whether you consume it. Smoking cannabis exposes you to PAHs, benzene, and other combustion carcinogens at levels comparable to, or in some cases exceeding, those from cigarette smoke. Edibles, tinctures, and capsules deliver THC without any combustion byproducts. Vaping falls somewhere in between: it avoids combustion temperatures but has its own concerns, particularly with unregulated products that may contain harmful additives.
The lung cancer risk data is almost entirely drawn from people who smoke cannabis. There’s essentially no epidemiological evidence connecting oral THC consumption to lung cancer or any other smoking-related cancer, because the mechanism of harm, burning plant material and inhaling the results, simply isn’t present. For someone choosing between consumption methods, this is probably the single most important practical takeaway from the existing research.